Journal of ethnopharmacology · 2025
Multi-target therapeutics of geraniin from Geranium wilfordii Maxim. and related species: Mechanisms and applications.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cai Jia, Wang Long, Xu Min, Zhu Shunpeng, Chen Yangxi, Zhong Jie, Li Jiaxin, Zhang Ping, Zhang Ting, Ye Qiang, Ao Hui
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Erodii Herba Geranii Herba (also called Laoguancao in China) is the dried aerial part of Geranium wilfordii Maxim., Geranium carolinianum L. or Erodium stephanianum Willd. It has developed into a natural remedy known for its anti-inflammatory, analgesic and hepatoprotective properties, and widely recognized within traditional Chinese medicine (TCM) and its cultural context. Given the traditional applications of Erodii Herba Geranii Herba, which underscore its potential as a promising source of bioactive compounds for pharmaceutical development, geraniin-one of its principal active constituents-has attracted increasing attention for its prospective development and utilization. Previous studies have demonstrated that geraniin exhibits a broad spectrum of pharmacological activities, including metabolic regulation, organ protection mediated through anti-inflammatory and antioxidant mechanisms, as well as antitumor and antiviral effects. Nevertheless, a systematic review of these pharmacological activities and their underlying mechanisms remains lacking.
AIM OF THE STUDY: This review focused on the pharmacological activities of geraniin and also summarized its availability, pharmacokinetics, and toxicity, thereby providing a solid theoretical foundation for its further development and practical utilization.
MATERIAL AND METHODS: The literature included in this review was identified through searches conducted in the PubMed and China National Knowledge Infrastructure (CNKI) databases using the keywords "Geraniin", "Pharmacology", and "Pharmacokinetics". A total of 99 articles were retrieved, excluding review articles. The retrieved publications covered a period from 1974 to 2025.
RESULTS: Geraniin demonstrated a range of pharmacological effects, including regulation of metabolism (glycolipid metabolism, blood pressure, and bone metabolism), protection of multiple organs (brain, cardiovascular, pulmonary, gastrointestinal, and renal systems), anti-tumor activity (against lung, breast, colorectal, and cervical cancers), and broad-spectrum antiviral properties. Notably, the multi-target actions of geraniin facilitated cross-disease modulation through involvement in the oxidative-inflammatory network (via NF-κB-Nrf2 and MAPK pathways) and the cell survival network (including PI3K/Akt and Wnt/β-catenin pathways), thereby underpinning its organ-protective effects, anti-tumor activity, and metabolic regulatory functions.
CONCLUSION: These attributes suggested that geraniin held promise as a multi-targeted therapeutic agent. Thus, this paper elucidated the possibility of exploiting the resources of geraniin as a pharmaceutical product.
AIM OF THE STUDY: This review focused on the pharmacological activities of geraniin and also summarized its availability, pharmacokinetics, and toxicity, thereby providing a solid theoretical foundation for its further development and practical utilization.
MATERIAL AND METHODS: The literature included in this review was identified through searches conducted in the PubMed and China National Knowledge Infrastructure (CNKI) databases using the keywords "Geraniin", "Pharmacology", and "Pharmacokinetics". A total of 99 articles were retrieved, excluding review articles. The retrieved publications covered a period from 1974 to 2025.
RESULTS: Geraniin demonstrated a range of pharmacological effects, including regulation of metabolism (glycolipid metabolism, blood pressure, and bone metabolism), protection of multiple organs (brain, cardiovascular, pulmonary, gastrointestinal, and renal systems), anti-tumor activity (against lung, breast, colorectal, and cervical cancers), and broad-spectrum antiviral properties. Notably, the multi-target actions of geraniin facilitated cross-disease modulation through involvement in the oxidative-inflammatory network (via NF-κB-Nrf2 and MAPK pathways) and the cell survival network (including PI3K/Akt and Wnt/β-catenin pathways), thereby underpinning its organ-protective effects, anti-tumor activity, and metabolic regulatory functions.
CONCLUSION: These attributes suggested that geraniin held promise as a multi-targeted therapeutic agent. Thus, this paper elucidated the possibility of exploiting the resources of geraniin as a pharmaceutical product.